About the Company
We do not have any company description for ANAPTYSBIO, INC at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ANAB News
AnaptysBio Inc ANAB
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
What Makes AnaptysBio, Inc. (ANAB) a New Buy Stock
The upgrade of AnaptysBio, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
Unveiling 4 Analyst Insights On AnaptysBio
Stay informed and make well-considered decisions with our Ratings Table. AnaptysBio Inc is a clinical-stage biotechnology ...
Wall Street Analysts Believe AnaptysBio, Inc. (ANAB) Could Rally 69.62%: Here's is How to Trade
AnaptysBio, Inc. (ANAB) closed the last trading session at $24.69, gaining 10.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
The Motley Fool recommends AnaptysBio. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of ...
AnaptysBio Stock (NASDAQ:ANAB), Analyst Ratings, Price Targets, Predictions
$21.53 62.56% HC Wainwright & Co.
Interview with the Co-Founder and CEO: Equillium Inc. (NASDAQ:EQ)
It’s been a few years since you last spoke with The Wall Street Transcript. Can you provide a refresher on the history and overview of the company? Mr. Steel: Sure. So we started Equillium back in ...
Need To Know: The Consensus Just Cut Its AnaptysBio, Inc. (NASDAQ:ANAB) Estimates For 2023
One thing we could say about the analysts on AnaptysBio, Inc. (NASDAQ:ANAB) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the ...
Unveiling 4 Analyst Insights On AnaptysBio
About AnaptysBio AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology.
AnaptysBio Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
AnaptysBio, Inc. (ANAB)
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 8.62% and 174.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Loading the latest forecasts...